Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

WVE-007

Oligonucleotide (siRNA) · Gene silencing · developed by Wave Life Sciences

Phase 1/2 Most advanced trial

WVE Developer

1 Registered trials

What is WVE-007?

WVE-007 is a stereopure siRNA oligonucleotide being studied in overweight and obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (siRNA)
Mechanism: Gene silencing
Therapy area: Metabolic
Developer: Wave Life Sciences (WVE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06842186	Phase 1/2	Overweight and Obesity	Recruiting	WVE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Overweight and Obesity

More from Wave Life Sciences

WVE-003 Phase 1/2 WVE-004 Phase 1/2 WVE-006 Phase 1/2 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2 WVE-210201 Phase 2/3 WVE-N531 Phase 1/2

Sources

ClinicalTrials.gov NCT06842186

Updated Oct 3, 2026. Something wrong or missing? Report it on the WVE page.

Follow WVE, the company behind WVE-007

See WVE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

WVE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z